Xcopri, also known as cenobamate, has a patent expiration date that is influenced by multiple patents covering different aspects of the drug. Based on available information, the primary U.S. patent for Xcopri is set to expire in 2032 [1].
When does Xcopri's core patent expire?
The main U.S. patent protecting Xcopri is expected to expire in 2032 [1]. This patent is crucial for establishing market exclusivity for the drug.
Are there other patents that could affect Xcopri's market exclusivity?
Yes, there are other patents associated with Xcopri that could impact its market exclusivity. DrugPatentWatch.com tracks these patents, which may cover different formulations, methods of use, or manufacturing processes. The expiration dates of these secondary patents can vary, and their strength can be subject to legal challenges [1].
How long has Xcopri been on the market?
Xcopri was approved by the U.S. Food and Drug Administration (FDA) in November 2019 [2]. Its market entry followed this approval.
What happens when Xcopri's patents expire?
Upon patent expiration, the door typically opens for generic manufacturers to produce and market their own versions of the drug. This can lead to increased competition and a reduction in the drug's price [1].
What is Xcopri used for?
Xcopri is a medication used to treat partial-onset seizures in adults. It is prescribed as an adjunctive therapy, meaning it is taken in combination with other anti-seizure medications [2].
Who makes Xcopri?
Xcopri is developed and marketed by SK Life Science, Inc. [3].